25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

KYTX (Kyverna Therapeutics, Inc. Common Stock) Stock Analysis
Buy, Hold or Sell?

Let's analyze Kyverna Therapeutics, Inc. Common Stock together

I guess you are interested in Kyverna Therapeutics, Inc. Common Stock. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Kyverna Therapeutics, Inc. Common Stock’s Financial Insights
  • 📈 Technical Analysis (TA) – Kyverna Therapeutics, Inc. Common Stock’s Price Targets

I'm going to help you getting a better view of Kyverna Therapeutics, Inc. Common Stock. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Kyverna Therapeutics, Inc. Common Stock

I send you an email if I find something interesting about Kyverna Therapeutics, Inc. Common Stock.

1. Quick Overview

1.1. Quick analysis of Kyverna Therapeutics, Inc. Common Stock (30 sec.)










1.2. What can you expect buying and holding a share of Kyverna Therapeutics, Inc. Common Stock? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.18
Expected worth in 1 year
$2.01
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-3.17
Return On Investment
-78.6%

For what price can you sell your share?

Current Price per Share
$4.03
Expected price per share
$2.06 - $3.82
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Kyverna Therapeutics, Inc. Common Stock (5 min.)




Live pricePrice per Share (EOD)
$4.03

2.2. Growth of Kyverna Therapeutics, Inc. Common Stock (5 min.)




Is Kyverna Therapeutics, Inc. Common Stock growing?

Current yearPrevious yearGrowGrow %
How rich?$224m$119.6m$162m57.5%

How much money is Kyverna Therapeutics, Inc. Common Stock making?

Current yearPrevious yearGrowGrow %
Making money-$36.3m-$18.9m-$17.3m-47.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Kyverna Therapeutics, Inc. Common Stock (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Kyverna Therapeutics, Inc. Common Stock?

Welcome investor! Kyverna Therapeutics, Inc. Common Stock's management wants to use your money to grow the business. In return you get a share of Kyverna Therapeutics, Inc. Common Stock.

First you should know what it really means to hold a share of Kyverna Therapeutics, Inc. Common Stock. And how you can make/lose money.

Speculation

The Price per Share of Kyverna Therapeutics, Inc. Common Stock is $4.03. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kyverna Therapeutics, Inc. Common Stock.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kyverna Therapeutics, Inc. Common Stock, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.18. Based on the TTM, the Book Value Change Per Share is $-0.79 per quarter. Based on the YOY, the Book Value Change Per Share is $2.52 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kyverna Therapeutics, Inc. Common Stock.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.03-25.6%-0.84-20.9%-0.44-10.9%-0.56-13.8%-0.56-13.8%-0.56-13.8%
Usd Book Value Change Per Share-0.99-24.4%-0.79-19.7%2.5262.4%0.5212.9%0.5212.9%0.5212.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.99-24.4%-0.79-19.7%2.5262.4%0.5212.9%0.5212.9%0.5212.9%
Usd Price Per Share1.93-4.52-6.21-4.29-4.29-4.29-
Price to Earnings Ratio-0.47--1.47--2.51--1.59--1.59--1.59-
Price-to-Total Gains Ratio-1.96--6.27-2.18--4.58--4.58--4.58-
Price to Book Ratio0.37-0.66-0.74-0.56-0.56-0.56-
Price-to-Total Gains Ratio-1.96--6.27-2.18--4.58--4.58--4.58-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.03
Number of shares248
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.790.52
Usd Total Gains Per Share-0.790.52
Gains per Quarter (248 shares)-196.51128.54
Gains per Year (248 shares)-786.03514.17
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-786-7960514504
20-1572-1582010281018
30-2358-2368015431532
40-3144-3154020572046
50-3930-3940025712560
60-4716-4726030853074
70-5502-5512035993588
80-6288-6298041134102
90-7074-7084046284616
100-7860-7870051425130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.010.00.00.0%0.010.00.00.0%0.010.00.00.0%0.010.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.07.01.020.0%2.07.01.020.0%2.07.01.020.0%2.07.01.020.0%
Dividend per Share0.00.04.00.0%0.00.010.00.0%0.00.010.00.0%0.00.010.00.0%0.00.010.00.0%
Total Gains per Share0.04.00.00.0%2.07.01.020.0%2.07.01.020.0%2.07.01.020.0%2.07.01.020.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Kyverna Therapeutics, Inc. Common Stock compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.985-0.792-20%2.516-139%0.518-290%0.518-290%0.518-290%
Book Value Per Share--5.1836.518-20%2.770+87%3.373+54%3.373+54%3.373+54%
Current Ratio--7.43910.352-28%10.527-29%8.797-15%8.797-15%8.797-15%
Debt To Asset Ratio--0.1410.114+24%1.276-89%0.977-86%0.977-86%0.977-86%
Debt To Equity Ratio--0.1640.129+27%0.040+307%0.370-56%0.370-56%0.370-56%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--289416477.000459047333.500-37%1414358476.000-80%650109562.000-55%650109562.000-55%650109562.000-55%
Eps---1.033-0.841-19%-0.439-57%-0.558-46%-0.558-46%-0.558-46%
Ev To Ebitda Ratio---1.526-3.409+123%-13.513+785%-5.430+256%-5.430+256%-5.430+256%
Free Cash Flow Per Share---1.039-0.783-25%-0.391-62%-0.517-50%-0.517-50%-0.517-50%
Free Cash Flow To Equity Per Share---1.049-0.790-25%1.901-155%0.397-364%0.397-364%0.397-364%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Market Cap174172167.000+52%83412477.000195133333.500-57%268389369.000-69%185409081.000-55%185409081.000-55%185409081.000-55%
Net Profit Margin----0%-0%-3.0130%-3.0130%-3.0130%
Operating Margin----0%-0%-2.9980%-2.9980%-2.9980%
Operating Ratio----0%-0%3.344-100%3.344-100%3.344-100%
Pb Ratio0.778+52%0.3720.662-44%0.743-50%0.562-34%0.562-34%0.562-34%
Pe Ratio-0.976-109%-0.467-1.473+215%-2.514+438%-1.595+241%-1.595+241%-1.595+241%
Price Per Share4.030+52%1.9304.515-57%6.210-69%4.290-55%4.290-55%4.290-55%
Price To Free Cash Flow Ratio-0.969-109%-0.464-1.667+259%-2.574+454%-1.697+265%-1.697+265%-1.697+265%
Price To Total Gains Ratio-4.091-109%-1.959-6.273+220%2.180-190%-4.582+134%-4.582+134%-4.582+134%
Quick Ratio--12.86917.055-25%14.746-13%13.263-3%13.263-3%13.263-3%
Return On Assets---0.171-0.119-31%-0.136-21%-0.131-23%-0.131-23%-0.131-23%
Return On Equity---0.199-0.135-32%-0.028-86%-0.089-55%-0.089-55%-0.089-55%
Total Gains Per Share---0.985-0.792-20%2.516-139%0.518-290%0.518-290%0.518-290%
Usd Book Value--224010000.000281704000.000-20%119694750.000+87%145760100.000+54%145760100.000+54%145760100.000+54%
Usd Book Value Change Per Share---0.985-0.792-20%2.516-139%0.518-290%0.518-290%0.518-290%
Usd Book Value Per Share--5.1836.518-20%2.770+87%3.373+54%3.373+54%3.373+54%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--289416477.000459047333.500-37%1414358476.000-80%650109562.000-55%650109562.000-55%650109562.000-55%
Usd Eps---1.033-0.841-19%-0.439-57%-0.558-46%-0.558-46%-0.558-46%
Usd Free Cash Flow---44915000.000-33825500.000-25%-16903250.000-62%-22323000.000-50%-22323000.000-50%-22323000.000-50%
Usd Free Cash Flow Per Share---1.039-0.783-25%-0.391-62%-0.517-50%-0.517-50%-0.517-50%
Usd Free Cash Flow To Equity Per Share---1.049-0.790-25%1.901-155%0.397-364%0.397-364%0.397-364%
Usd Market Cap174172167.000+52%83412477.000195133333.500-57%268389369.000-69%185409081.000-55%185409081.000-55%185409081.000-55%
Usd Price Per Share4.030+52%1.9304.515-57%6.210-69%4.290-55%4.290-55%4.290-55%
Usd Profit---44635000.000-36354750.000-19%-18979000.000-57%-24097400.000-46%-24097400.000-46%-24097400.000-46%
Usd Revenue----0%-0%28200.000-100%28200.000-100%28200.000-100%
Usd Total Gains Per Share---0.985-0.792-20%2.516-139%0.518-290%0.518-290%0.518-290%
 EOD+5 -3MRQTTM+4 -28YOY+7 -253Y+10 -245Y+10 -2410Y+10 -24

3.3 Fundamental Score

Let's check the fundamental score of Kyverna Therapeutics, Inc. Common Stock based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.976
Price to Book Ratio (EOD)Between0-10.778
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than112.869
Current Ratio (MRQ)Greater than17.439
Debt to Asset Ratio (MRQ)Less than10.141
Debt to Equity Ratio (MRQ)Less than10.164
Return on Equity (MRQ)Greater than0.15-0.199
Return on Assets (MRQ)Greater than0.05-0.171
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Kyverna Therapeutics, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose3.600
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Fundamental data was last updated by Penke on 2025-06-29 15:22:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Kyverna Therapeutics, Inc. Common Stock earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Kyverna Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kyverna Therapeutics, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-301.3%+301.3%
5Y-301.3%10Y-301.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--93.6%+93.6%
TTM--140.9%+140.9%
YOY--197.6%+197.6%
3Y-301.3%-248.5%-52.8%
5Y-301.3%-343.4%+42.1%
10Y-301.3%-496.2%+194.9%
4.3.1.2. Return on Assets

Shows how efficient Kyverna Therapeutics, Inc. Common Stock is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kyverna Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • -17.1% Return on Assets means that Kyverna Therapeutics, Inc. Common Stock generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kyverna Therapeutics, Inc. Common Stock:

  • The MRQ is -17.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.1%TTM-11.9%-5.2%
TTM-11.9%YOY-13.6%+1.7%
TTM-11.9%5Y-13.1%+1.2%
5Y-13.1%10Y-13.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.1%-11.6%-5.5%
TTM-11.9%-11.6%-0.3%
YOY-13.6%-11.4%-2.2%
3Y-13.1%-11.8%-1.3%
5Y-13.1%-12.0%-1.1%
10Y-13.1%-13.7%+0.6%
4.3.1.3. Return on Equity

Shows how efficient Kyverna Therapeutics, Inc. Common Stock is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kyverna Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • -19.9% Return on Equity means Kyverna Therapeutics, Inc. Common Stock generated $-0.20 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kyverna Therapeutics, Inc. Common Stock:

  • The MRQ is -19.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -13.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.9%TTM-13.5%-6.4%
TTM-13.5%YOY-2.8%-10.7%
TTM-13.5%5Y-8.9%-4.6%
5Y-8.9%10Y-8.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.9%-13.5%-6.4%
TTM-13.5%-14.9%+1.4%
YOY-2.8%-14.6%+11.8%
3Y-8.9%-16.8%+7.9%
5Y-8.9%-17.5%+8.6%
10Y-8.9%-19.9%+11.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Kyverna Therapeutics, Inc. Common Stock.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Kyverna Therapeutics, Inc. Common Stock is operating .

  • Measures how much profit Kyverna Therapeutics, Inc. Common Stock makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kyverna Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kyverna Therapeutics, Inc. Common Stock:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-299.8%+299.8%
5Y-299.8%10Y-299.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--232.5%+232.5%
TTM--250.5%+250.5%
YOY--209.2%+209.2%
3Y-299.8%-234.1%-65.7%
5Y-299.8%-346.1%+46.3%
10Y-299.8%-477.5%+177.7%
4.3.2.2. Operating Ratio

Measures how efficient Kyverna Therapeutics, Inc. Common Stock is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kyverna Therapeutics, Inc. Common Stock:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y3.344-3.344
5Y3.34410Y3.3440.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.111-2.111
TTM-2.694-2.694
YOY-3.096-3.096
3Y3.3443.652-0.308
5Y3.3444.745-1.401
10Y3.3446.614-3.270
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Kyverna Therapeutics, Inc. Common Stock.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Kyverna Therapeutics, Inc. Common Stock is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.44 means the company has $7.44 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kyverna Therapeutics, Inc. Common Stock:

  • The MRQ is 7.439. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.352. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.439TTM10.352-2.913
TTM10.352YOY10.527-0.175
TTM10.3525Y8.797+1.555
5Y8.79710Y8.7970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.4393.661+3.778
TTM10.3523.846+6.506
YOY10.5274.140+6.387
3Y8.7974.688+4.109
5Y8.7975.746+3.051
10Y8.7976.147+2.650
4.4.3.2. Quick Ratio

Measures if Kyverna Therapeutics, Inc. Common Stock is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kyverna Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A Quick Ratio of 12.87 means the company can pay off $12.87 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kyverna Therapeutics, Inc. Common Stock:

  • The MRQ is 12.869. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.055. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.869TTM17.055-4.186
TTM17.055YOY14.746+2.309
TTM17.0555Y13.263+3.792
5Y13.26310Y13.2630.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.8692.848+10.021
TTM17.0553.169+13.886
YOY14.7463.786+10.960
3Y13.2634.311+8.952
5Y13.2635.703+7.560
10Y13.2636.368+6.895
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Kyverna Therapeutics, Inc. Common Stock.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Kyverna Therapeutics, Inc. Common Stock assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kyverna Therapeutics, Inc. Common Stock to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.14 means that Kyverna Therapeutics, Inc. Common Stock assets are financed with 14.1% credit (debt) and the remaining percentage (100% - 14.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kyverna Therapeutics, Inc. Common Stock:

  • The MRQ is 0.141. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.114. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.141TTM0.114+0.027
TTM0.114YOY1.276-1.163
TTM0.1145Y0.977-0.863
5Y0.97710Y0.9770.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1410.329-0.188
TTM0.1140.349-0.235
YOY1.2760.331+0.945
3Y0.9770.340+0.637
5Y0.9770.349+0.628
10Y0.9770.379+0.598
4.5.4.2. Debt to Equity Ratio

Measures if Kyverna Therapeutics, Inc. Common Stock is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kyverna Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A Debt to Equity ratio of 16.4% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kyverna Therapeutics, Inc. Common Stock:

  • The MRQ is 0.164. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.129. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.164TTM0.129+0.035
TTM0.129YOY0.040+0.089
TTM0.1295Y0.370-0.241
5Y0.37010Y0.3700.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1640.379-0.215
TTM0.1290.437-0.308
YOY0.0400.414-0.374
3Y0.3700.450-0.080
5Y0.3700.464-0.094
10Y0.3700.515-0.145
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Kyverna Therapeutics, Inc. Common Stock generates.

  • Above 15 is considered overpriced but always compare Kyverna Therapeutics, Inc. Common Stock to the Biotechnology industry mean.
  • A PE ratio of -0.47 means the investor is paying $-0.47 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kyverna Therapeutics, Inc. Common Stock:

  • The EOD is -0.976. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.467. Based on the earnings, the company is expensive. -2
  • The TTM is -1.473. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.976MRQ-0.467-0.508
MRQ-0.467TTM-1.473+1.005
TTM-1.473YOY-2.514+1.041
TTM-1.4735Y-1.595+0.122
5Y-1.59510Y-1.5950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.976-2.356+1.380
MRQ-0.467-2.077+1.610
TTM-1.473-2.574+1.101
YOY-2.514-3.760+1.246
3Y-1.595-3.773+2.178
5Y-1.595-6.193+4.598
10Y-1.595-6.876+5.281
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kyverna Therapeutics, Inc. Common Stock:

  • The EOD is -0.969. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.464. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.667. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.969MRQ-0.464-0.505
MRQ-0.464TTM-1.667+1.203
TTM-1.667YOY-2.574+0.907
TTM-1.6675Y-1.697+0.029
5Y-1.69710Y-1.6970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.969-3.246+2.277
MRQ-0.464-2.705+2.241
TTM-1.667-3.704+2.037
YOY-2.574-4.402+1.828
3Y-1.697-5.070+3.373
5Y-1.697-8.477+6.780
10Y-1.697-9.305+7.608
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Kyverna Therapeutics, Inc. Common Stock is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.37 means the investor is paying $0.37 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kyverna Therapeutics, Inc. Common Stock:

  • The EOD is 0.778. Based on the equity, the company is cheap. +2
  • The MRQ is 0.372. Based on the equity, the company is cheap. +2
  • The TTM is 0.662. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.778MRQ0.372+0.405
MRQ0.372TTM0.662-0.290
TTM0.662YOY0.743-0.081
TTM0.6625Y0.562+0.100
5Y0.56210Y0.5620.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.7782.038-1.260
MRQ0.3721.843-1.471
TTM0.6622.125-1.463
YOY0.7432.442-1.699
3Y0.5622.492-1.930
5Y0.5623.652-3.090
10Y0.5624.311-3.749
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Kyverna Therapeutics, Inc. Common Stock.

4.8.3. Insider Transactions

Insiders are holding 12.037% of the shares of Kyverna Therapeutics, Inc. Common Stock.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-12Northpond Ventures Iii Gp, LlcBUY45000022
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets260,655
Total Liabilities36,645
Total Stockholder Equity224,010
 As reported
Total Liabilities 36,645
Total Stockholder Equity+ 224,010
Total Assets = 260,655

Assets

Total Assets260,655
Total Current Assets247,651
Long-term Assets13,004
Total Current Assets
Cash And Cash Equivalents 56,865
Short-term Investments 185,784
Other Current Assets 5,002
Total Current Assets  (as reported)247,651
Total Current Assets  (calculated)247,651
+/-0
Long-term Assets
Property Plant Equipment 8,803
Long-term Assets Other 4,201
Long-term Assets  (as reported)13,004
Long-term Assets  (calculated)13,004
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities33,292
Long-term Liabilities3,353
Total Stockholder Equity224,010
Total Current Liabilities
Short-term Debt 3,585
Accounts payable 8,472
Other Current Liabilities 12,763
Total Current Liabilities  (as reported)33,292
Total Current Liabilities  (calculated)24,820
+/- 8,472
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt3,353
Long-term Liabilities  (as reported)3,353
Long-term Liabilities  (calculated)3,353
+/-0
Total Stockholder Equity
Retained Earnings -308,155
Accumulated Other Comprehensive Income -1
Other Stockholders Equity 532,166
Total Stockholder Equity (as reported)224,010
Total Stockholder Equity (calculated)224,010
+/-0
Other
Cash and Short Term Investments 242,649
Common Stock Shares Outstanding 43,216
Liabilities and Stockholders Equity 260,655
Net Debt -49,927
Net Invested Capital 224,010
Net Working Capital 214,359
Property Plant and Equipment Gross 12,737
Short Long Term Debt Total 6,938



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-31
> Total Assets 
66,924
0
389,984
92,486
75,195
389,984
363,116
339,196
304,645
260,655
260,655304,645339,196363,116389,98475,19592,486389,984066,924
   > Total Current Assets 
53,251
51,322
375,488
79,410
60,664
375,488
348,823
325,374
290,601
247,651
247,651290,601325,374348,823375,48860,66479,410375,48851,32253,251
       Cash And Cash Equivalents 
37,735
-51,322
224,287
22,967
34,647
224,287
131,618
104,663
96,621
56,865
56,86596,621104,663131,618224,28734,64722,967224,287-51,32237,735
       Short-term Investments 
13,587
102,644
145,507
54,307
22,896
145,507
214,619
216,924
189,358
185,784
185,784189,358216,924214,619145,50722,89654,307145,507102,64413,587
       Other Current Assets 
1,929
0
5,694
2,136
3,121
5,694
2,586
3,787
4,622
5,002
5,0024,6223,7872,5865,6943,1212,1365,69401,929
   > Long-term Assets 
13,673
-51,322
14,496
13,076
14,531
14,496
14,293
13,822
15,919
13,004
13,00415,91913,82214,29314,49614,53113,07614,496-51,32213,673
       Property Plant Equipment 
12,441
0
12,752
11,071
10,610
12,752
12,506
11,382
10,656
8,803
8,80310,65611,38212,50612,75210,61011,07112,752012,441
       Long-term Assets Other 
678
-51,322
1,744
2,005
3,356
1,174
1,213
2,440
5,263
4,201
4,2015,2632,4401,2131,1743,3562,0051,744-51,322678
> Total Liabilities 
140,921
0
28,993
204,292
206,592
28,993
29,607
36,486
38,058
36,645
36,64538,05836,48629,60728,993206,592204,29228,9930140,921
   > Total Current Liabilities 
11,954
0
21,865
16,874
19,859
21,865
23,478
30,985
33,756
33,292
33,29233,75630,98523,47821,86519,85916,87421,865011,954
       Short-term Debt 
2,277
0
3,718
2,796
2,920
7,436
7,740
7,862
3,940
3,585
3,5853,9407,8627,7407,4362,9202,7963,71802,277
       Accounts payable 
1,451
0
7,451
3,022
4,358
7,451
4,861
9,932
4,624
8,472
8,4724,6249,9324,8617,4514,3583,0227,45101,451
       Other Current Liabilities 
8,226
0
10,696
11,056
12,581
6,978
10,877
8,880
25,192
12,763
12,76325,1928,88010,8776,97812,58111,05610,69608,226
   > Long-term Liabilities 
128,967
0
7,128
187,418
186,733
7,128
6,129
5,501
4,302
3,353
3,3534,3025,5016,1297,128186,733187,4187,1280128,967
       Capital Lease Obligations 
10,564
0
0
9,640
9,079
10,846
9,999
9,136
8,242
6,938
6,9388,2429,1369,99910,8469,0799,6400010,564
       Long-term Liabilities Other 
6
0
0
0
0
0
0
296
0
0
002960000006
> Total Stockholder Equity
-73,997
46,677
360,991
-111,806
-131,397
360,991
333,509
302,710
266,587
224,010
224,010266,587302,710333,509360,991-131,397-111,806360,99146,677-73,997
   Retained Earnings -308,155-263,520-226,031-191,539-162,736-136,043-115,376-162,7360-75,677
   Accumulated Other Comprehensive Income 
-26
-73,997
-1
5
4
-1
-37
153
105
-1
-1105153-37-145-1-73,997-26
   Capital Surplus 0000000000
   Treasury Stock0000000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-2,133
Gross Profit0-2,133
 
Operating Income (+$)
Gross Profit0
Operating Expense-142,604
Operating Income-142,604-142,604
 
Operating Expense (+$)
Research Development110,340
Selling General Administrative30,131
Selling And Marketing Expenses0
Operating Expense142,604140,471
 
Net Interest Income (+$)
Interest Income15,359
Interest Expense-142
Other Finance Cost-0
Net Interest Income15,217
 
Pretax Income (+$)
Operating Income-142,604
Net Interest Income15,217
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-127,477-157,731
EBIT - interestExpense = -144,879
-254,954
-127,335
Interest Expense142
Earnings Before Interest and Taxes (EBIT)-144,737-127,335
Earnings Before Interest and Taxes (EBITDA)-142,604
 
After tax Income (+$)
Income Before Tax-127,477
Tax Provision-0
Net Income From Continuing Ops-127,477-127,477
Net Income-127,477
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net15,127-15,217
 

Technical Analysis of Kyverna Therapeutics, Inc. Common Stock
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kyverna Therapeutics, Inc. Common Stock. The general trend of Kyverna Therapeutics, Inc. Common Stock is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kyverna Therapeutics, Inc. Common Stock's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Kyverna Therapeutics, Inc. Common Stock Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kyverna Therapeutics, Inc. Common Stock.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 3.625 < 3.75 < 3.82.

The bearish price targets are: 2.57 > 2.38 > 2.06.

Know someone who trades $KYTX? Share this with them.👇

Kyverna Therapeutics, Inc. Common Stock Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kyverna Therapeutics, Inc. Common Stock. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kyverna Therapeutics, Inc. Common Stock Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kyverna Therapeutics, Inc. Common Stock.

Kyverna Therapeutics, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) ChartKyverna Therapeutics, Inc. Common Stock Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kyverna Therapeutics, Inc. Common Stock. The current adx is .

Kyverna Therapeutics, Inc. Common Stock Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kyverna Therapeutics, Inc. Common Stock.

Kyverna Therapeutics, Inc. Common Stock Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kyverna Therapeutics, Inc. Common Stock.

Kyverna Therapeutics, Inc. Common Stock Daily Relative Strength Index (RSI) ChartKyverna Therapeutics, Inc. Common Stock Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kyverna Therapeutics, Inc. Common Stock.

Kyverna Therapeutics, Inc. Common Stock Daily Stochastic Oscillator ChartKyverna Therapeutics, Inc. Common Stock Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kyverna Therapeutics, Inc. Common Stock.

Kyverna Therapeutics, Inc. Common Stock Daily Commodity Channel Index (CCI) ChartKyverna Therapeutics, Inc. Common Stock Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kyverna Therapeutics, Inc. Common Stock.

Kyverna Therapeutics, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) ChartKyverna Therapeutics, Inc. Common Stock Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kyverna Therapeutics, Inc. Common Stock.

Kyverna Therapeutics, Inc. Common Stock Daily Williams %R ChartKyverna Therapeutics, Inc. Common Stock Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kyverna Therapeutics, Inc. Common Stock.

Kyverna Therapeutics, Inc. Common Stock Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kyverna Therapeutics, Inc. Common Stock.

Kyverna Therapeutics, Inc. Common Stock Daily Average True Range (ATR) ChartKyverna Therapeutics, Inc. Common Stock Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kyverna Therapeutics, Inc. Common Stock.

Kyverna Therapeutics, Inc. Common Stock Daily On-Balance Volume (OBV) ChartKyverna Therapeutics, Inc. Common Stock Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kyverna Therapeutics, Inc. Common Stock.

Kyverna Therapeutics, Inc. Common Stock Daily Money Flow Index (MFI) ChartKyverna Therapeutics, Inc. Common Stock Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kyverna Therapeutics, Inc. Common Stock.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Kyverna Therapeutics, Inc. Common Stock Daily Candlestick Chart
DateCandlestick Pattern
2025-07-10Three White Soldiers Candle Pattern

6.4. Technical Score

Let's check the technical score of Kyverna Therapeutics, Inc. Common Stock based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose3.600
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Kyverna Therapeutics, Inc. Common Stock with someone you think should read this too:
  • Are you bullish or bearish on Kyverna Therapeutics, Inc. Common Stock? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kyverna Therapeutics, Inc. Common Stock? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kyverna Therapeutics, Inc. Common Stock

I send you an email if I find something interesting about Kyverna Therapeutics, Inc. Common Stock.


Comments

How you think about this?

Leave a comment

Stay informed about Kyverna Therapeutics, Inc. Common Stock.

Receive notifications about Kyverna Therapeutics, Inc. Common Stock in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.